| Patients | CF (36 events)†| PCD (15 events)* |
---|
N | (%) | 5-year EFS (%) | HR | CI95% | p | Events (N) | 10-year EFS (%) | HR | CI95% | p | Events (N) |
---|
PSA-DT
| Â | Â | Â | Â | Â |
<0.001
| Â | Â | Â | Â |
0.029
| Â |
  Missing | 12 | 7 | - | NE |  |  | 3 | - | NE |  |  | 0 |
  >15 | 71 | 42 | 98 | 1 | Ref |  | 5 | 93 | 1 | Ref |  | 1 |
  9-14.9 | 27 | 16 | 77 | 3.28 | 0.9-11.9 | 0.09 | 5 | 86 | 4.60 | 0.41-52.0 | 0.22 | 2 |
  3-8,9 | 46 | 27 | 69 | 6.44 | 2.26-18.3 |
<0.001
| 16 | 70 | 13.7 | 1.51-124 |
0.020
| 8 |
  <3 | 14 | 8 | 59 | 11.2 | 3.35-37.7 |
<0.001
| 7 | 49 | 27.5 | 2.64-286 |
0.006
| 4 |
pN-stage
| Â | Â | Â | Â | Â |
0.002
| Â | Â | Â | Â |
0.020
| Â |
  NX | 69 | 41 |  | 1 | Ref |  | 9 |  | 1 | Ref |  | 3 |
  N0 | 98 | 57 |  | 1.38 | 0.61-3.13 | 0.45 | 24 |  | 1.20 | 0.31-4.59 | 0.80 | 11 |
  N1 | 3 | 2 |  | 19.1 | 3.69-100 |
<0.001
| 2 | Â | 32.5 | 2.61-405 |
0.007
| 1 |
- Significant p-values in bold (threshold p ≤ 0.05).
-
Abbreviations: BF biochemical failure, CF Clinical failure, NS not significant, the characteristic is removed by the backward conditional analysis due to insignificance, NE not entered, PCD prostate cancer death, PSA Prostate specific antigen, PSA-DT PSA doubling time in months; †a positive non-apical margin, PNI, vasc inf, pT stage and Gleason were removed by the backward conditional model due to insignificance in all models. *Due to the low number of events the model was carefully analyzed in advance with the inclusion and removal of variables in an enter analysis to find the most significant in advance before doing the final model with the three variables; PSA-DT, Gleason score and pN-stage.